

## 6. Literaturverzeichnis

**Abramson, Stuart; Niles, John L.:** Anticoagulation in continuous renal replacement therapy. *Current Opinion in Nephrology and Hypertension* 8: S. 701-707, 1999.

**Ahmad, S.; R. Callan; J. J. Cole; C. R. Blagg:** Dialysate made from dry chemicals using citric acid increases dialysis dose. *Am J Kidney Dis* 35: S. 493-499, 2000.

**Ambühl, P. M.; R. P. Wüthrich; W. Korte; L. Schmid; R. Krapf:** Plasma hypercoaguability in haemodialysis patients: impact of dialysis and anticoagulation. *Nephrol Dial Transplant* 12: S. 2355-2364, 1997.

**Anastassiades, E.; D. A. Lane; H. Ireland; A. Flynn; J. R. Curtis:** A low molecular weight heparin ("fragmin") for routine hemodialysis: A crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin. *Clin Nephrol* 32: S. 290-296, 1989.

**Apsner, R.; M. Schwarzenhofer; K. Derfler; C. Zauner; K. Ratheiser; A. Kranz:** Impairment of citrate metabolism in acute hepatic failure. *Wien Klin Wochenschr* 109/4: S. 123-127, 1997.

**Apsner, R; W. Druml:** More on Anticoagulation for Continuous Hemofiltration. *The New England Journal of Medicine*, Vol. 338, No. 2: S. 131-132, 1998.

**Apsner, Robert; Heidi Buchmayer; Thomas Lang; Beate Unver; Wolfgang Speiser; Gere Sunder-Plassmann; Walter H. Hörl:** Simplified Citrate Anticoagulation for High-Flux Hemodialysis, *American Journal of Kidney Diseases*, Vol 38, No 5 (November): S. 979-987, 2001.

**Bellomo, R.; Teede, H.; Boyce, N.:** Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. *Intens Care Med* 19: S. 329-332, 1993.

**Boehler, J;** Kapitel "Hämodialyse" 516-556 aus : Kuhlmann et al., *Nephrologie* 2003

**Boehler, J.; P. Schollmeyer; B. Dressl; G. Dobos; W. H. Hoerl:** Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: Dissociation of complement activation and neutropenia from neutrophil degranulation. *J Am Soc Nephrol* 7: S. 234-241, 1996.

**Boon D. M. S.; H. H. D. M. van Vliet, R. Zietse, M. C. Kappers-Klunne:** The presence of antibodies against a PF4-heparin complex in patients on haemodialysis. *Thromb Haemostas* 76: S. 480, 1996.

**Bos JC, Grooteman MP, van Houte AJ, Schorl M, van Limbeek J, Nube MJ;** Low polymorphonuclear cell degranulation during citrate und heparin dialysis. *Nephrol Dial Transplant*; 12 1387-1393, 1997.

**von Brecht, J. H.; M. J. Flanigan; R. M. Freeman; V. S. Lim:** Regional anticoagulation: Hemodialysis with hypertonic trisodium citrate. *Am J Kidney Dis* 8: S. 196-201, 1986.

**Brieger, D. B.; M. Koon-Hou; K. Kottke-Marchant; E. J. Topol:** Heparin-induced thrombocytopenia. *JACC* 31: S. 1449-1459, 1998.

**Calatzis A., M. Toepfer, W. Schramm, M. Spannagl, H. Schiff:** Citrat Anticoagulation for Extracorporeal Circuits: Effects von Whole Blood Coagulation Activation and Clot Formation, *Nephron* 2001; 89: 233-236

**Caruana, R. J.; R. M. Raja; J. V. Bush; M. S. Kramer; S. J. Goldstein:** Heparin free dialysis: comparative data and results in high risk patients. *Kidney Int* 31, S. 1351-1355, 1987.

**Caruana, R. J.; M. C. Smith; D. Clyne; J. W. Crow; J. M. Zinn; J. H. Diehl:** Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis. *Blood Purif* 9: S. 296-304, 1991.

**Casati, S.; M. Moia; G. Graziani; et al.:** Hemodialysis without anticoagulants: efficiency and hemostatic aspects. *Clin Nephrol* 21: S. 102-105, 1984.

**Chuang, Peale; Chirag Parikh, Robert F. Reilly:** A Case Review: Anticoagulation in Hemodialysis Patients with Heparin-Induced Thrombocytopenia, *Am J Nephron* 21: 226-231, 2001.

**Coté, Charles J.; Lambertus J. Drop; David C. Hoaglin; Alfred L. Daniels; Elizabeth T. Young:** Ionized Hypocalcemia after Fresh Frozen Plasma Administration to Thermally Injured Children, *Anaesth analg* 1988, 67, 152-60

**Davenport A., Mehta S.,** Acute Dialysis Quality initiative, Workgroup 6, Internet

**Denlinger, J. K.; M. L. Nahrwold; P. S. Gibbs; J. H. Lecky:** Hypocalcaemia during rapid blood transfusion in anaesthetized man, *Br. J. Anaesth.* (1976), 48, 995

**Dhondt, Annemieke; Raymond Vanholder; Christian Tielemans; Griet Glorieux; Marie-Anne Waterloos; Rita De Smet; Nobert Lameire:** Effect of Regional Citrate Anticoagulation on Leukopenia, Complement Activation, und Expression of Leukocyte Surface Molecules during Hemodialysis with Unmodified Cellulose Membranes, *Nephron* 2000, 85, 334-342

**Evenepoel, Pieter, Bart Maes, Johan Vanwalleghem, Dirk Kuypers, Thierry Messiaen, Yves Vanrenterghem:** Regional Citrate Anticoagulation for Hemodialysis using a Conventional Calcium-Containing Dialysate. *American Journal of Kidney Diseases*, Vol. 39, No. 2 (February), 2002, 315-323.

**Faber, L. M.; P. M. De Vries; P. L. Oe; J. Van Der Meulen; A. J. Donker:** Zitrates hemodialysis. *Neth J Med* 37: S. 219-224, 1990.

**Farrell, P. C.; R. A. Ward; K. Schindhelm; F. A. Gotch:** Precise anticoagulation for routine hemodialysis. *J Lab Clin Med* 92: S. 164-176, 1978.

**Fischer, M. J.; A. van de Loo; J. Bohler:** Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. *Kidney Int* 72: S. 46-50, 1999.

**Flanigan, M. J.; J. H. van Brecht; R. M. Freeman; V. S. Lim:** Reducing the hemorrhagic complications of dialysis: A controlled comparison of low-dose heparin and zitrates anticoagulation. *Am J Kidney Dis* 9: S. 147-153, 1987.

**Flanigan, M. J.; L. Pillsbury; G. Sadewasser; V. S. Lim:** Regional hemodialysis anticoagulation: Hypertonic tri-sodium zitrates or anticoagulant zitrates dextrose-A. *Am J Kidney Dis* 27: S. 519-524, 1996.

**Franz H.E., Walter H. Hörl:** Blutreinigungsverfahren, Technik und Klinik, Georg Thieme Verlag Stuttgart New York 1997

**Gabutti, Luca; Claudio Marone; Giuseppe Colucci; Francesca Duchini; Carlo Schönholzer:** Zitrates anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. *Intensive Care Med* 28: 1419-1425, 2002.

**Gotch, F. A.; M. L. Keen:** Precise control of minimal heparinization for high-bleeding risk hemodialysis. *Trans Am Soc Artif Intern Organs* 23: S. 168-175, 1977.

**Grand S.M., Goa K.L.:** Illoprost. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. *Drugs* Jun 43:6; 889-924, 1992.

**Greinacher, A.; S. Zinn; V. Wizemann; U. V. Birk:** Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysis (letter). *Lancet* 349: S. 764, 1996.

**Greinacher, A.; H. Volpel; U. Janssens; V. Hach-Wunderle; B. Kemkes-Matthes; P. Eichler; H. G. Mueller-Velten:** Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. *Circulation* 99: S. 73-80, 1999.

**Hertel, J;** Kapitel "Antikoagulation" 182-198 aus : Daugirdas, J et al, Handbook of Dialysis 2000

**Hocken, A. G.; P. L. Hurst:** Zitrates Regional Anticoagulation in Haemodialysis. *Nephron* 46; S. 7-10; 1987.

**Hofbauer, R.; Moser D.; Frass, M.; Oberbauer, R.; Kaye, A. D.; Wagner, O.; Kapiotis, S.; Druml, W.:** Effect of anticoagulation on blood membrane interactions during hemodialysis. *Kidney International* 56: S. 1578-1583, 1999.

**Janssen M.J.F.M.; P.C. Huijgens; A.A. Bouman; P.L. Oe; A.J.M. Donker; J van der Meulen:** Zitrates versus heparin anticoagulation in chronic haemodialysis, *Nephrol Dial Transplant* 8: 1228-1233, 1993.

**Janssen, M. J.; P. C. Huijgens; A. A. Bouman; P. L. Oe; J. van der Meulen:** Zitrates anticoagulation and divalent cations in hemodialysis. *Blood Purif* 12: S. 308-316, 1994.

**Janssen, M. J.; J. K. Deegens; T. H. Kapinga; J. R. Beukhof; P. C. Huugens; A. C. van Loenen; J. van der Meulen:** Zitrates compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients. *Kidney Int* 49: S. 806-813, 1996.

**Jeffrey, R. F.; Khan, A. A.; Douglas, J. T.; Will, E. J.; Davison, A. M.:** Anticoagulation with low molecular weight heparin (Framin) during continuous hemodialysis in the intensive care unit. *Artif. Org.* 17: S. 717-720, 1993.

**Kaplan, A.A. und Petrillo, R.:** Regional heparinization for continuous arterio-venous hemofiltration (CAVH). *ASAIO Trans* 33: S. 312-315, 1987.

**Kathisan S et al.,** *J Thrombosis and Thrombolysis* 13 (1), 41-47, 2002

**Kelleher, Stephen P.; Gerald Schulman:** Severe Metabolic Alkalosis Complicating Regional Zitrates Hemodialysis. *American Journal of Kidney Diseases*, Vol. IX, No. 3 (March): S. 235-236, 1987.

**Kern, H.; S. Ziemer; W. J. Kox:** Bleeding after intermittent or continuous r-hirudin during CVVH. *Intensive Care Med* 25: S. 1311-1314, 1999.

**Kleinschmidt et al.,** *Anästhesist* 48, 771-785, 1999.

**Kramer P, Wigger W., Rieger J., Matthali D., Scheler F.:** Arteriovenous hemofiltration: A new and simple method for treatment of overhydrated patients resistant to diuretics. *Klin Wochenschr.* 55: 1121-1122, 1977

**Kutsogiannis, D.; I. Mayers; W. Chin; R. Gibney:** Continuous venovenous hemodiafiltration. *Am J Kidney Dis* 35: S. 802-811, 2000.

**Langenecker SA, Felfernig M., Werba A., Mueller CM, Chari A., Zimpfer M.,** Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. *Crit Care Med*, 22, 1774-1781, 1994

**Lindsay, R. M.:** Practical use of anticoagulants. In *Replacement of Renal Function by Dialysis*; edited by Drukker, W; F. M. Parsons; J. F. Maher. Boston, Martinus Nijhoff, S. 201-222, 1983.

**Löffler, G.:** Intermediärstoffwechsel I: Zitratcyclus, 14. Aus Löffler, G. und P. E. Petrides: Physiologische Chemie, Springer-Verlag, 1988.

**Lohr, James, W.; Sharon Slusher; Dennis Diederich:** Safety of Regional Hemodialysis in Acute Renal Failure. American Journal of Kidney Diseases, Vol. XIII, No. 2 (February) 1989, S. 104-107.

**Luzzatto, G.; M. Bertoli; G. Cella; F. Fabris; B. Zaia; A. Girolami:** Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factors pathway inhibitor plasma antigen level in chronic dialysis. Thromb Res 89: S. 115-122, 1998.

**Macias, W. L.:** Choice of Replacement Fluid/Dialysate in Continuous Renal Replacement Therapy, American Journal of Kidney Diseases, Vol. 28, No 5, Supp 3, S.15-20,1996.

**Maher, J. F.; L. Lapierre; G. E. Schreiner; M. Geiger; F. B. Westervelt:** Regional heparinization for hemodialysis. Technique and clinical experiences. N Engl J Med 268: S. 451-456, 1963.

**Martin, P.Y., J.-C. Chevrolet, P. Suter, H. Favre:** Anticoagulation in Patients Treated by Continuous Venovenous Hemofiltration: A retrospective Study; American Journal of Kidney Diseases, Vol 24, N 5, pp 806-812, 1994.

**Mehta, Ravindra L.; Brian R. McDonald; May M. Aguilar, David M. Ward:** Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney International, Vol. 38: S. 976-981, 1990.

**Mehta, R. L.; B. R. McDonald; D. M. Ward:** Regional Citrate Anticoagulation for Continuous Arteriovenous Hemodialysis. Aus Siebert, H. G.; Mann, H.; Stummvoll, H. K. (Hrsg.): Continuous Hemofiltration. Contrib Nephrol. Basel, Karger. Vol. 93, S. 210-214, 1991.

**Mehta, R. L.; J. T. Bestoso; D. M. Ward:** Experience with regional citrate anticoagulation for continuous renal replacement therapy. J Am Soc Nephrol 4: S.368 (abstract), 1993.

**Mehta, R. L.:** Anticoagulation Strategies for Continuous Renal Replacement Therapies: What Works? American Journal of Kidney Diseases, Vol. 25, No. 5: S. 8-14, 1996.

**Meier-Kriesche, H.-U.; K. W. Finkel; J. J. Gitomer; T. DuBose:** Unexpected severe hypocalcemia during continuous venovenous hemodialysis with regional citrate anticoagulation. Am J Kidney Dis 33: S. 1-4, 1999.

**Meier-Kriesche, Herwig-Ulf, Jeremy Gitomer, Kevin Finkel, Thomas Du Bose:** Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med Vol. 29, No. 4: S. 748-752, 2001.

**van der Meulen, J.; M. J. F. M. Janssen; P. N. J. Langedijk; A. A. Bouman; P. L.:** Citrate anticoagulation and dialysate with reduced buffer content in chronic hemodialysis. Clin Nephrol 37: S. 36-41, 1992.

**Morita, Y.; R. W. Johnson; R. E. Dorn; D. S. Hall:** Regional anticoagulation during hemodialysis using citrate. Am J Med Sci 242: S. 32-43, 1961.

**Mujais, S. K.; H. Chimeh:** Heparin free hemodialysis using heparin coated hemophan. ASAIO J 42: S. M538-M541, 1996.

**Nowak G. und Bucha E.,** Semin Thromb Hemost, 22, 197-202, 1996.

**Ouseph, Rosemary; Richard A. Ward:** Anticoagulation for Intermittent Hemodialysis. Seminars in Dialysis, Vol. 13, No. 3 (May-June) 2000, S. 181-187.

**Palsson, R.; J. Niles:** Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 55: S. 1991-1997, 1999.

**Pinnick, R. V.; T. B. Wiegman; D. A. Diederich:** Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med 308: S. 258-261, 1983.

**Ramao, J. E.; M. A. Fadil; E. Sabbage; M. Marcondes:** Hemodialysis without anticoagulant: Haemostasis parameters, fibrinogen kinetic, and dialysis efficiency. Nephrol Dial Transplant 12: S. 106-110, 1997.

**Remuzzi G:** Bleeding in renal failure, Lancet, 105: 1205-1208, 1988

**Ronco, C.; R. Bellomo:** Complications with Continuous Renal Replacement Therapy. American Journal of Kidney Disease, Vol. 28, No. 5, Suppl 3: S. S100-S104, 1996.

**Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G.** Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 356(9223):26-30, 2000

**Rossert J.,** Kidney International, , 60; 804-817; 2001

**Saltissi, D.; C. Morgan; J. Westhuyzen; H. Healy:** Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant 14: S. 2698-2703, 1999.

**Sanders, P. W.; H. Taylor; J. J. Curtis:** Hemodialysis without anticoagulation. Am J Kidney Dis 5: S. 32-35, 1985.

**Seaton R, Duncan K, Pinnick R, Diederich D, Wiegmann T:** Regional citrat anticoagulation in chronic hemodialysis patients. *Trans Am Soc Artif Intern Organs* 29: 414-418, 1983.

**Schiele, F.; A. Vuillemenot; P. Kramarz; Y. Kieffer; T. Anguenot; Y. Bernard; J. P. Bassand:** Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. *Am J Hematol* 50: S. 20-25, 1995.

**Schrader, J.; W. Stibbe; V. W. Armstrong, et al.:** Comparison of low molecular weight to standard heparin in hemodialysis/hemofiltration. *Kidney Int* 33: S. 890-896, 1988.

**Schwab, S. J.; J. J. Onorato; L. R. Sharar; P. A. Dennis:** Hemodialysis without anticoagulation. One-year prospective trial in hospitalized patients at risk for bleeding. *Am J Med* 83: S. 405-410, 1987.

**Silverstein, Freya J.; James R. Oster; Guido O. Perez; Barry J. Materson; Rafael A. Lopez; Kamel Al-Reshaid:** Metabolic Alkalosis Induced by Regional Citrate Hemodialysis. *Trans Am Soc Artif Organs (ASAIO) Transactions*, Vol. XXXV: S. 22-25, 1989.

**Suki, Wadi N.; R. David Bounelous; Steven Yocom; Carol A. Conlin; Joyce E. Crater; Lillie M. Silas; Judy A. Wright; Charlotte A. Kelly:** Citrate for Regional Anticoagulation - Effects on Blood PO<sub>2</sub>, Ammonia, and Aluminium. *ASAIO Transactions* 1988, 34, S. 524-527.

**Swartz, R. D.:** Hemorrhage during high-risk hemodialysis using controlled heparinization. *Nephron* 28: S. 65-69, 1981.

**Swartz, R. D., F.K. Port:** Preventing hemorrhage in high-risk hemodialysis: regional versus low-dose heparin. *Kidney Int.* 16: 513-518, 1979.

**Tandy-Porcet, B., B. Tardy, J. Reynaud et al.:** Efficacy and safety of danaparoid sodium (Org 10172) in critically ill patient with heparin-associated thrombocytopenia, *Chest* 115: 1616-1620, 1999.

**Tolwani Ashita; Ruth C. Campbell; Margaret B. Schenk; Michael Allon; David G. Warnock:** Simplified citrate anticoagulation for continuous renal replacement therapy, *Kidney International*, Vol. 60: S.. 370-374. 2001.

**Vanholder R.; A. Camez; N. Veys; A. Van Loo; A. M. Dhondt; S. Ringoir:** Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. *Thromb Haemost* 77: S. 650-655, 1997.

**Vargas, O. H.; C. von Heymann; M. Lipps; S. Ziemer; C. Ronco; H. H. Neumayer; S. Morgera; M. Welte; W. J. Kox; C. Spies:** Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. *Intensive Care Med* 27: S. 673-679, 2001.

**Ward, D. M.; R. L. Mehta:** Extracorporeal management of acute renal failure patients at high risk of bleeding. *Kidney International* 43: S. 237-244, 1993.

**Warkentin, T. E.; M. N. Levine; J. Hirsh; P. Horsewood; R. S. Roberts; M. Gent; J. G. Kelton:** Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. *N Engl J Med* 332: S. 1330-1335, 1995.

**Warkentin, T. E.; L. J. Elavathil; C. P. Hayward; M. A. Johnston; J. I. Russett; J. G. Kelton:** The pathogenesis of venous limb gangrene complicating heparin-induced thrombocytopenia. *Ann Intern Med* 127: S. 804-812, 1997.

**Warkentin, T. E.; B. H. Chong; A. Greinacher:** Heparin-induced thrombocytopenia: Towards consensus. *Thromb Haemost* 79: S. 1-7, 1998.

**Warkentin, T. E.; R. L. Barkin:** Newer Strategies for treatment of heparin-induced thrombocytopenia. *Pharmacotherapy* 19: S. 181-195, 1999.

**van de Wetering, J.; Westendorp, R. G., van der Hoeven, J. G. ; Stolk, B.; Feuth, J. D. Chang, P. C.:** Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. *J. Am. Soc. Nephrol.* 7: S. 145-150, 1996.

**Wiegmann, T.B.; M.L. MacDougall; D.A. Diederich:** Dialysis Leukopenia, Hypoxemia, and Anaphylatoxin Formation: Effect of Membrane, Bath, and Citrate Anticoagulation, *American Journal of Kidney Diseases*, Vol XI, No 5 (May), 1988, S. 418-424

**Woods, H. F.; M. J. Weston; S. Bunting:** Hemodialysis without heparin. *Proc Eur Dial Transplant Assoc* 15: S. 122-129, 1978.

**Yamamoto, S.; M. Koide; M. Matsuo; S. Suzuki; M. Ohtaka; S. Saika; T. Matsuo:** Heparin-induced thrombocytopenia in hemodialysis patients. *Am J Kid Dis* 25: S. 82-85, 1996.

**Zaloga, G.:** Hypocalcemia in critically ill patients. *Crit Care Med* 20: S. 251-262, 1992.

**Zusman, R. M.; R. H. Rubin; A. E. Cato:** Hemodialysis using prostacyclin instead of heparin as the sole antithrombic agent. *N Engl J Med* 304: S. 934-939, 1981.